COVID-19: China approves vaccine for use by military only without phase III study

By on .

By Daniel R. Lucey M.D., MPH, FIDSA

Today China approved a Covid-19 vaccine, for use only by its military. Importantly, however, this approval occurred despite the vaccine not having undergone a phase III efficacy study.

As reported by Josephine Ma in the South China Morning Post, this vaccine was developed by the company CanSino Biologics (Tianjin) and a research institute at the Academy of Military Science that is headed by Major General Chen Wei. The vaccine cannot be given to civilians at this time.

The vaccine is termed “Ad5 vectored Covid-19 vaccine”. It combines a recombinant adenovirus type-5 vectored spike glycoprotein of the SARS-CoV-2 virus. The phase I vaccine was the first (or among the first) to be published in a peer review journal. Although at least one phase II study (NCT04341389) has taken place, it has not yet been published.

The phase I trial took place in Wuhan. Published online May 22, in The Lancet, it was titled: “Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomized, first-in-human trial.”

In this phase I study, a single dose was given to 108 volunteers who were between ages 18 and 60, with  36 persons receiving the low-dose, 36 the middle-dose, and 36 the high dose of the vaccine. Both T-cell and antibody (B-cell) responses were measured. The authors noted that in the high dose group “severe fever, fatigue, dyspnea, muscle pain, and joint pain were reported in some of the recipients”.

They also noted other potential concerns: ”However, aside from pre-existing anti-Ad5 immunity, there is concern about the increased risk of HIV-1 acquisition associated with Ad5 activated CD4 T-cells. Although the association between HIV-1 acquisition risk and Ad5 vectored vaccine is controversial and its mechanism is unclear, the potential risks should be taken into account in studies with this viral vector delivery platform.” (The authors referenced a phase 2 HIV vaccine study in South Africa that also used a recombinant adenovirus type 5 published by Gray G. et al in The Lancet Infectious Diseases 2014; 14: 388-396).

On the website of CanSinoBIO, it is reported that they had also worked with the Academy of Military Medical Sciences to develop and receive approval for an Adenovirus 5 vectored vaccine against Ebola.

Dr. Daniel Lucey

Daniel Lucey, M.D. MPH, FIDSA, FACP, is an infectious diseases physician and adjunct professor of infectious diseases at Georgetown University Medical Center, a senior scholar at the Georgetown University O’Neil Institute, Anthropology Research Associate, Smithsonian Museum of Natural History and a member of the Infectious Diseases Society of America Global Health Committee.He has served as a volunteer medical responder to outbreaks that included the West Africa Ebola crisis. He has collected information on outbreaks starting in 2001 with cases of anthrax in 2001, and including smallpox vaccination 2002, SARS 2003, H5N1 Flu 2004, MERS in 2013, and Ebola in April, 2014, He has gathered, and  updated information on the spread of the coronavirus here since Jan. 6.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.